title: A catalytically active Jak2 is required for the angiotensin II-dependent activation of Fyn.
abstract: Recent work with interleukins has shown a convergence of tyrosine phosphorylation signal transduction cascades at the level of the Janus and Src families of tyrosine kinases. Here we demonstrate that activation of the seven-transmembrane AT(1) receptor by angiotensin II induces a physical association between Jak2 and Fyn, in vivo. This association requires the catalytic activity of Jak2 but not Fyn. Deletion studies indicate that the region of Jak2 that binds Fyn is located between amino acids 1 and 240. Studies of the Fyn SH2 and SH3 domains demonstrate that the SH2 domain plays the primary role in Jak2/Fyn association. Not surprisingly, this domain shows a marked preference for tyrosine-phosphorylated Jak2. Surface plasmon resonance estimated the dissociation equilibrium constant (K(d)) of this association to be 2.36 nM. Last, in vivo studies in vascular smooth muscle cells show that, in response to angiotensin II, Jak2 activation is required for Fyn activation and induction of the c-fos gene. The significance of these data is that Jak2, in addition to serving as a critical angiotensin II activated signal transduction kinase, also functions as a docking protein and participates in the activation of Fyn by providing phosphotyrosine residues that bind the SH2 domain of Fyn.
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
authors.forename: P P
authors.initials: PP
authors.lastname: Sayeski
authors.forename: M S
authors.initials: MS
authors.lastname: Ali
authors.forename: A
authors.initials: A
authors.lastname: Safavi
authors.forename: M
authors.initials: M
authors.lastname: Lyles
authors.forename: S O
authors.initials: SO
authors.lastname: Kim
authors.forename: S J
authors.initials: SJ
authors.lastname: Frank
authors.forename: K E
authors.initials: KE
authors.lastname: Bernstein
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D019556:COS Cells; D002478:Cells, Cultured; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D017930:Genes, Reporter; D053614:Janus Kinase 2; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009154:Mutation; D010766:Phosphorylation; D011485:Protein Binding; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051076:Proto-Oncogene Proteins c-fyn; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000378:metabolism; D015398:Signal Transduction; D020349:Surface Plasmon Resonance; D014162:Transfection; D020032:Tyrphostins / Q000494:pharmacology; D018909:src Homology Domains
chemical_list: D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D020032:Tyrphostins; C095512:alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide; D000804:Angiotensin II; D011505:Protein-Tyrosine Kinases; D053614:Janus Kinase 2; D051076:Proto-Oncogene Proteins c-fyn